Details of the Drug Pharmacogenomic Perturbation Atlas

5'-iodotubercidin Drug Info

5-Iodotubercidin; 24386-93-4; 5-iodotubericidin; 7-Deaza-7-iodoadenosine; 7-iodo-7-deazaadenosine; 7-iodotubercidin; (2R,3R,4S,5R)-2-(4-AMINO-5-IODO-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-3,4-DIOL; CHEMBL99203; CHEBI:40167; 5-iodo-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine; NSC 113939; 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,5-iodo-7-b-D-ribofuranosyl-; 7H-Pyrrolo(2,3-d)pyrimidin-4-amine, 5-iodo-7-beta-D-ribofuranosyl-

Cross-matching ID

PubChem CID

101649230

TTD Drug ID

D00RDY

General Information of Drug (ID: DML5ZEJ)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Graft-versus-host disease	2.21	0.00e+0	32/42 (76.19%)	IL1A;HLA-DQA1;HLA-C;...
Type I diabetes mellitus	2.07	0.00e+0	38/43 (88.37%)	IL1A;GAD1;HLA-DQA1;...
Rheumatoid arthritis	2.00	4.60e-3	78/93 (83.87%)	IL1A;CXCL8;ATP6AP1;...
Viral myocarditis	1.93	3.45e-3	53/60 (88.33%)	SGCB;CXADR;HLA-DQA1;...
ECM-receptor interaction	1.90	2.76e-3	80/88 (90.91%)	THBS1;VWF;ITGB5;...
Phagosome	1.90	2.30e-3	118/152 (77.63%)	ATP6AP1;THBS1;ITGB5;...
Cholesterol metabolism	1.89	1.97e-3	44/50 (88%)	VDAC1;PLTP;LRPAP1;...
Cell adhesion molecules	1.87	3.45e-3	118/148 (79.73%)	SDC2;HLA-DQA1;HLA-C;...
AGE-RAGE signaling pathway in diabetic complications	1.85	4.60e-3	97/100 (97%)	EGR1;IL1A;CXCL8;...
Lysosome	1.84	6.90e-3	115/128 (89.84%)	CTSC;ATP6AP1;CTSZ;...
Oxidative phosphorylation	1.82	1.00e-2	93/133 (69.92%)	ATP6AP1;NDUFA1;NDUFA4L2;...
Allograft rejection	1.81	1.15e-2	32/38 (84.21%)	HLA-DQA1;HLA-C;HLA-F;...
Malaria	1.74	2.65e-2	44/50 (88%)	SDC2;CXCL8;CD81;...
PPAR signaling pathway	1.73	2.76e-2	66/74 (89.19%)	SCP2;SCD5;PLTP;...
Circadian entrainment	1.70	3.40e-2	85/97 (87.63%)	GUCY1A1;GRIA2;GNG10;...
Relaxin signaling pathway	1.67	4.49e-2	114/129 (88.37%)	MMP9;GNG10;FOS;...
Leukocyte transendothelial migration	1.67	4.22e-2	90/114 (78.95%)	MMP9;THY1;CYBB;...
Complement and coagulation cascades	1.66	4.29e-2	76/85 (89.41%)	CLU;VWF;SERPING1;...
Vitamin digestion and absorption	1.65	4.58e-2	17/24 (70.83%)	SLC5A6;SLC19A1;SCARB1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	0.37uM - 12.5uM	6H, 24H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.04uM - 10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.04uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.04uM - 10uM	6H, 24H

Normal (Transformed)

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.04uM - 10uM	6H, 24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.04uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.04uM - 10uM	6H, 24H

Normal (Fibroblast)

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.04uM - 10uM	6H, 24H